Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | DAO | P14920 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827232 | 0.77 | CYP3A4 (0.46) | MAPTSMN1; SMN2FTOALOX15MEN1 | |
| SCHEMBL2432148 | 0.73 | ALDH1A1 (0.55) | MAPTSMN1; SMN2MEN1ALDH1A1CYP3A4 | |
| SCHEMBL3972917 | 0.72 | NR4A2 (0.64) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL2432823 | 0.72 | CREB1 (0.48) | MAPTSMN1; SMN2MEN1ALDH1A1CYP3A4 | |
| SCHEMBL7481676 | 0.71 | BACE1 (0.58) | IDH1MAPTSMN1; SMN2ALOX15MEN1 | |
| SCHEMBL674221 | 0.70 | CHRM2 (0.50) | SMN1; SMN2MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL2682843 | 0.69 | MEN1 (0.54) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL10177678 | 0.69 | CYP2C19 (0.50) | MAPTSMN1; SMN2MEN1ALDH1A1CYP3A4 | |
| SCHEMBL1585486 | 0.69 | IDH1 (1.00) | IDH1KDM4EDAO | |
| SCHEMBL8398561 | 0.69 | APP (0.76) | MAPTSMN1; SMN2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3709962-B1 | ANHYDROUS COMPOSITION COSMETICALLY ACCEPTABLE FOR USE AS NAIL POLISH | INT LACQUERS (LU) | 2022-01-26 | — | — | EP | disclosed |
| US-20210186837-A1 | COSMETICALLY ACCEPTABLE ANHYDROUS COMPOSITION FOR NAIL VARNISH | INTERNATIONAL LACQUERS (LU) | 2021-06-24 | — | — | US | disclosed |
| US-20210186837-A1 | COSMETICALLY ACCEPTABLE ANHYDROUS COMPOSITION FOR NAIL VARNISH | INTERNATIONAL LACQUERS (LU) | 2021-06-24 | — | — | US | disclosed |
| EP-2542076-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| US-9399651-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | Merck, Sharp & Dohme Corp. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9024032-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-04-04 | — | — | US | disclosed |
| EP-2542076-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011109254-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | IDH1 824/4885MAPT 220/4885SMN1; SMN2 2558/4885 |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | IDH1 824/4885MAPT 220/4885SMN1; SMN2 2558/4885 |
| US-20210186837-A1 | COSMETICALLY ACCEPTABLE ANHYDROUS COMPOSITION FOR NAIL VARNISH | NACA, TYR, PRKX | IDH1 3553/4885MAPT 163/4885SMN1; SMN2 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.